<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14221">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921750</url>
  </required_header>
  <id_info>
    <org_study_id>CHEXU03</org_study_id>
    <nct_id>NCT02921750</nct_id>
  </id_info>
  <brief_title>Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin</brief_title>
  <acronym>PD-497314</acronym>
  <official_title>A Randomised Multi-centre Non-inferiority Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigation is designed as an open, randomized, non-inferiority, multi-centre
      investigation.

      212 subjects will be randomised (subjects lost to follow-up will be replaced). Subjects to
      be included will suffer from an exuding venous or mixed ulcer of predominantly venous
      origin. Subjects will either be randomized to Exufiber® or Aquacel® Extra using centralized
      randomization
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visits are planned for baseline followed by 1, 2, 3, 4 and 6 weeks post treatment. The
      sub-group of at least 50 subjects (from the wound care centers in Germany) will also be
      followed at week 8, 12, 16, 20, and 24 post treatment or until wound is healed if earlier.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Reduction</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative reduction of sloughy tissue, measured with photo analysis</measure>
    <time_frame>6 - 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound area reduction ( cm2)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linear advance of the wound margin according to Gilman's formula</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Debrided wound (%)</measure>
    <time_frame>6 - 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of additional debridements</measure>
    <time_frame>6 - 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain during debridement measured by VAS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the condition of peri-wound skin measured by investigator judgement</measure>
    <time_frame>6 - 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain in connection of removal of the dressing, measured by VAS by the patient</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in wound status including exudate management, measured by investigator judgement</measure>
    <time_frame>6 - 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician's and subject's opinion related to the dressing. Both opinion measured by questionnaires</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>6 - 24 weeks</time_frame>
    <description>EQ5D-3L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events/Adverse device effects</measure>
    <time_frame>6 - 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of debridement measured by investigator judgement</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Wound healing</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>Dressing Exufiber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive dressing Exufiber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dressing Aquacel Extra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive Aquacel Extra</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exufiber</intervention_name>
    <description>Gelling fibre dressing</description>
    <arm_group_label>Dressing Exufiber</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aquacel Extra</intervention_name>
    <description>Gelling fibre dressing</description>
    <arm_group_label>Dressing Aquacel Extra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent i.e. subject must be able to understand and sign the
             Patient Information and Consent Form

          2. Both gender ≥18 years old

          3. Ulcer moderately or strongly exudative justifying the use of an absorbent dressing

          4. History of compression at least two weeks before inclusion

          5. Wound covered with slough ≥70%

          6. 1.3&lt; ABPI ≥0.7

          7. Ulcer duration 6 weeks to 36 months

          8. Ulcer size 3 cm2 -100 cm2

          9. Target ulcer at least 3 cm away from any other lesion

        Exclusion Criteria:

          1. Known allergy/hypersensitivity to the dressings

          2. Pregnant or breastfeeding

          3. Circumferential wounds (the entire wound should be able to be captured on a single
             image/photo)

          4. Subjects who will have problems following the protocol

          5. Subjects included in other ongoing clinical investigation evaluating wound dressings
             at present or during the past 30 days

          6. Patient with a systemic infection not controlled by suitable antibiotic treatment

          7. Clinically infected wound according to the judgement of the investigator (heat, pain,
             swelling, redness or purulent secretion)

          8. Wound covered with black necrosis

          9. Dry wounds

         10. Malignant wound degeneration

         11. Current treatment with radiotherapy, chemotherapy, immunosuppressant drugs or high
             doses of oral corticosteroids if any

         12. Subject with deep vein thrombosis within 3 months prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caroline Gröndahl, Msc</last_name>
    <email>caroline.grondahl@molnlycke.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Copenhagen NV</state>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Surgery</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Services Rhumatologie et Dermatologie</name>
      <address>
        <city>Chambray Les Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wundzentrum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86152</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diabeteszentrum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Venenzentrum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79008</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chirurgie München Nord</name>
      <address>
        <city>München</city>
        <zip>80939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lund university Hospital,</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skellefteå Lasarett</name>
      <address>
        <city>Skellefteå</city>
        <zip>931 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset (KI SÖS), Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>September 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wound reduction wound healing, venous ulcers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
